Association between the Use of Proton Pump Inhibitors and Cognitive Impairment in Older Adults
##plugins.themes.bootstrap3.article.details##
Objective: The objective was to describe the association between the presence of cognitive impairment and the use of proton pump inhibitors (PPI) in the older adult population in Bogotá, Colombia. Methods: We analyzed the SABE Bogotá study. This study included 2,000 people over 60 years, in a cross-sectional sample. The variable of interest was the alteration in the modified Mini-Mental State Examination (MMSE-M). It was related to the use of PPI. This analysis was adjusted for factors such as sex, age, years of schooling and marital status. Results: The average age was 71.17±8.05 years, 63.4% were women. We found that 20.7% used PPIs, with an average duration of use of 74.8±93.76 months. 12.6% of older adults had altered MMSE-M, with a higher prevalence in PPI users (25.4% vs. 20.02%; p: 0.049). In the multivariate analysis, an association of adjusted risk increase was found between cognitive impairment and the use of PPIs for ≥24 months (OR: 1.90; CI: 1.11-3.24; p = 0.018). Conclusions: This study shows an association of a significant increase in the risk between using PPIs for ≥ 24 months and developing cognitive impairment. More studies are needed to conclude a direct causality relationship.
2. World Health Organization. The top 10 causes of death 2017 [internet]. Avalaible at: http://www.who.int/mediacentre/factsheets/fs310/en/.
3. Beerens HC, Zwakhalen SM, Verbeek H, Ruwaard D, Hamers JP. Factors associated with quality of life of people with dementia in long-term care facilities: a systematic review. Int J Nurs Stud. 2013;50(9):1259-70. doi: https://doi.org/10.1016/j.ijnurstu.2013.02.005.
4. Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, et al. Dementia prevention, intervention, and care. Lancet. 2017;390(10113):2673-2734. doi: https://doi.org/10.1016/S0140-6736(17)31363-6.
5. Delgado Silveira E, Montero Errasquín B, Muñoz García M, Vélez-Díaz-Pallares M, Lozano Montoya I, Sánchez-Castellano C, et al. [Improving drug prescribing in the elderly: a new edition of STOPP/START criteria]. Rev Esp Geriatr Gerontol. 2015;50(2):89-96.
6. Wijarnpreecha K, Thongprayoon C, Panjawatanan P, Ungprasert P. Proton pump inhibitors and risk of dementia. Ann Transl Med. 2016;4(12):240.
7. Mossner J. The indications, applications, and risks of proton pump inhibitors. Dtsch Arztebl Int. 2016;113(27-28):477-83. doi: https://doi.org/10.3238/arztebl.2016.0477.
8. Moriarty F, Bennett K, Cahir C, Fahey T. Characterizing potentially inappropriate prescribing of proton pump inhibitors in older people in primary care in ireland from 1997 to 2012. J Am Geriatr Soc. 2016;64(12):e291-e6.
9. Badiola N, Alcalde V, Pujol A, Munter LM, Multhaup G, Lleo A, et al. The proton-pump inhibitor lansoprazole enhances amyloid beta production. PloS one. 2013;8(3):e58837.
10. Majumdar A, Cruz D, Asamoah N, Buxbaum A, Sohar I, Lobel P, et al. Activation of microglia acidifies lysosomes and leads to degradation of Alzheimer amyloid fibrils. Mol Biol Cell. 2007;18(4):1490-6.
11. Peláez M, Palloni A, Albala C, Alfonso JC, Ham-Chande R, Hennis A, et al. SABE - Survey on Health, Well-Being, and Aging in Latin America and the Caribbean, 2000. Inter-university Consortium for Political and Social Research (ICPSR) [distributor]; 2005.
12. Cano-Gutiérrez C, Bordaz MG, Reyes-Ortiz C, Arciniegas AJ, Samper-Ternent R . Evaluación de factores asociados al estado funcional en ancianos de 60 años o más en Bogotá, Colombia. Biomédica. 2017;37(supl 1). doi: http://dx.doi.org/10.7705/biomedica.v37i1.3197.
13. Cano-Gutiérrez C, Samper-Ternent R, Cabrera J, Rosselli D. [Medication use among older adults in Bogota, Colombia]. Rev Peru Med Exp Salud Publica. 2016;33(3):419-24. doi: https://doi.org/10.17843/rpmesp.2016.333.2292.
14. Albala C, Lebrao ML, León Díaz EM, Ham-Chande R, Hennis AJ, Palloni A, et al. [The Health, Well-Being, and Aging ("SABE") survey: methodology applied and profile of the study population]. Rev Panam Salud Publica. 2005;17(5-6):307-22.
15. Icaza M, Albala C. Minimental State Examinations (MMSE) del estudio de demencia en Chile: Analisis Estadístico. Washington, D.C; 1999.
16. Rodríguez L, Juan de J. Demencia: prevalencia, factores de riesgo, impacto y prevención, el estudio 10/66. Inf Psiquiátr. 2015;219:9-20.
17. Gutiérrez-Robledo LM, Arrieta-Cruz I. [Dementia in Mexico: The need for a National Alzheimer s Plan]. Gaceta Médica de Mexico. 2015;151(5):667-73.
18. Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H, Johns H. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective. Alzheimer's & Dementia. 2015;11(6):718-26.
19. Lovden M, Xu W, Wang HX. Lifestyle change and the prevention of cognitive decline and dementia: what is the evidence? Curr Opin Psychiatry. 2013;26(3):239-43. doi: https://doi.org/10.1097/YCO.0b013e32835f4135.
20. Gomm W, von Holt K, Thome F, Broich K, Maier W, Fink A, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73(4):410-6.
21. Goldstein FC, Steenland K, Zhao L, Wharton W, Levey AI, Hajjar I. Proton pump inhibitors and risk of mild cognitive impairment and dementia. J Am Geriatr Soc. 2017;65(9):1969-74.